These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19925842)

  • 21. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current guidelines applicable for the approval of topically applied dermatological drugs in the EU.
    Straube MD; Zesch A
    Fundam Clin Pharmacol; 2004 Oct; 18(5):503-11. PubMed ID: 15482371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ; Mire-Sluis A
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
    Hennessy S; Leonard CE; Platt R
    Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting.
    Lamarque V; Merle L; Demarez JP;
    Therapie; 2008; 63(4):301-9. PubMed ID: 18937910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar peptides: need for pharmacovigilance.
    Joshi SR
    J Assoc Physicians India; 2011 Apr; 59 Suppl():44-7. PubMed ID: 21818998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Legislation relating to nutraceuticals in the European Union with a particular focus on botanical-sourced products.
    Gulati OP; Berry Ottaway P
    Toxicology; 2006 Apr; 221(1):75-87. PubMed ID: 16487647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.